As of Jul 18
| +0.03 / +1.08%|
The 4 analysts offering 12-month price forecasts for Proteostasis Therapeutics Inc have a median target of 12.50, with a high estimate of 25.00 and a low estimate of 5.00. The median estimate represents a +346.43% increase from the last price of 2.80.
The current consensus among 4 polled investment analysts is to Buy stock in Proteostasis Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.